Tianjin Lisheng Pharmaceutical Co.,Ltd.

XSEC:002393 Stock Report

Market Cap: CN¥4.2b

Tianjin Lisheng PharmaceuticalLtd Past Earnings Performance

Past criteria checks 2/6

Tianjin Lisheng PharmaceuticalLtd has been growing earnings at an average annual rate of 22.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 4.8% per year. Tianjin Lisheng PharmaceuticalLtd's return on equity is 3.7%, and it has net margins of 14.9%.

Key information

22.3%

Earnings growth rate

22.2%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-4.8%
Return on equity3.7%
Net Margin14.9%
Next Earnings Update21 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Tianjin Lisheng PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:002393 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,265188453119
30 Jun 241,24037444891
31 Mar 241,182374425103
31 Dec 231,153362429102
30 Sep 231,15632444191
30 Jun 231,189112466103
31 Mar 231,17698467100
01 Jan 231,14794449102
30 Sep 221,158137481111
30 Jun 221,119133469107
31 Mar 221,071128450101
01 Jan 221,092122466101
30 Sep 211,0612744894
30 Jun 211,1141348293
31 Mar 211,1361051078
31 Dec 201,141954773
30 Sep 201,32113364382
30 Jun 201,37415668690
31 Mar 201,513178773102
31 Dec 191,615188813120
30 Sep 191,61321583975
30 Jun 191,58920583874
31 Mar 191,54418879887
31 Dec 181,50418576992
30 Sep 181,366122707129
30 Jun 181,273107564188
31 Mar 181,138117479144
01 Jan 181,029117420101
30 Sep 1797513734885
30 Jun 179151253940
31 Mar 178961143860
31 Dec 168471163500
30 Sep 16792743270
30 Jun 16769773040
31 Mar 167791102950
31 Dec 157751142910
30 Sep 157621043010
30 Jun 157591043070
31 Mar 15725753010
31 Dec 14774933230
30 Sep 148511293370
30 Jun 149251783450
31 Mar 141,0162523650

Quality Earnings: 002393 has high quality earnings.

Growing Profit Margin: 002393's current net profit margins (14.9%) are lower than last year (28%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002393's earnings have grown significantly by 22.3% per year over the past 5 years.

Accelerating Growth: 002393's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002393 had negative earnings growth (-41.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 002393's Return on Equity (3.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 17:27
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tianjin Lisheng Pharmaceutical Co.,Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peng YanChangjiang Securities Co. LTD.
Jie YaoEverbright Securities Co. Ltd.
Ting HuangSinolink Securities Co., Ltd.